35/120
1.5 / 5 stars
All 120 Win/Lose results shown below
AMRN Roast Me summary
AMARIN CORP PLC\UK (AMRN). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAMRN / S&P 10.24% / 15.20% |
LoseAMRN / S&P -15.10% / 15.00% |
LoseAMRN / S&P AMRN unavailable / 50.40% |
| 2026-Q11/3 |
WinAMRN / S&P 3.58% / -4.33% |
LoseAMRN / S&P 1.24% / 11.30% |
LoseAMRN / S&P AMRN unavailable / 27.70% |
| 2025-Q40/3 |
LoseAMRN / S&P -14.77% / 2.65% |
LoseAMRN / S&P -6.55% / 9.00% |
LoseAMRN / S&P AMRN unavailable / 13.40% |
| 2025-Q30/3 |
LoseAMRN / S&P 0.99% / 8.12% |
LoseAMRN / S&P -5.93% / 4.61% |
LoseAMRN / S&P AMRN unavailable / 13.45% |
| 2025-Q21/3 |
WinAMRN / S&P 80.22% / 10.94% |
LoseAMRN / S&P -17.15% / 4.83% |
LoseAMRN / S&P AMRN unavailable / 10.63% |
| 2025-Q10/3 |
LoseAMRN / S&P -8.16% / -4.27% |
LoseAMRN / S&P -22.83% / 4.98% |
LoseAMRN / S&P AMRN unavailable / 10.57% |
| 2024-Q40/3 |
LoseAMRN / S&P -22.22% / 2.41% |
LoseAMRN / S&P -25.51% / 5.25% |
LoseAMRN / S&P AMRN unavailable / 6.15% |
| 2024-Q30/3 |
LoseAMRN / S&P -8.70% / 5.89% |
LoseAMRN / S&P -25.25% / 5.89% |
LoseAMRN / S&P AMRN unavailable / 6.11% |
| 2024-Q20/3 |
LoseAMRN / S&P -22.47% / 4.28% |
LoseAMRN / S&P -23.53% / 5.38% |
LoseAMRN / S&P AMRN unavailable / 5.12% |
| 2024-Q10/3 |
LoseAMRN / S&P 2.30% / 10.56% |
LoseAMRN / S&P -23.04% / 5.71% |
LoseAMRN / S&P AMRN unavailable / 5.59% |
| 2023-Q40/3 |
LoseAMRN / S&P -5.43% / 11.69% |
LoseAMRN / S&P -16.87% / 6.81% |
LoseAMRN / S&P AMRN unavailable / 7.78% |
| 2023-Q30/3 |
LoseAMRN / S&P -22.69% / -3.27% |
LoseAMRN / S&P -23.85% / 7.52% |
LoseAMRN / S&P AMRN unavailable / -5.03% |
| 2023-Q20/3 |
LoseAMRN / S&P -20.67% / 8.74% |
LoseAMRN / S&P -27.19% / 9.50% |
LoseAMRN / S&P AMRN unavailable / -8.57% |
| 2023-Q11/3 |
WinAMRN / S&P 23.97% / 7.50% |
LoseAMRN / S&P -32.69% / 10.77% |
LoseAMRN / S&P AMRN unavailable / -15.69% |
| 2022-Q41/3 |
WinAMRN / S&P 11.01% / 7.56% |
LoseAMRN / S&P -36.69% / 11.88% |
LoseAMRN / S&P -1400.00% / -17.99% |
| 2022-Q30/3 |
LoseAMRN / S&P -26.85% / -4.88% |
LoseAMRN / S&P -30.12% / 13.47% |
LoseAMRN / S&P AMRN unavailable / -1.41% |
| 2022-Q20/3 |
LoseAMRN / S&P -54.71% / -16.10% |
LoseAMRN / S&P -23.34% / 13.71% |
LoseAMRN / S&P -2600.00% / 11.04% |
| 2022-Q11/3 |
WinAMRN / S&P -2.37% / -4.60% |
LoseAMRN / S&P -10.91% / 15.97% |
LoseAMRN / S&P AMRN unavailable / 42.23% |
| 2021-Q40/3 |
LoseAMRN / S&P -33.92% / 11.03% |
LoseAMRN / S&P -5.03% / 15.00% |
LoseAMRN / S&P AMRN unavailable / 96.40% |
| 2021-Q31/3 |
WinAMRN / S&P 16.44% / 0.58% |
LoseAMRN / S&P 2.69% / 10.77% |
LoseAMRN / S&P AMRN unavailable / 69.42% |
| 2021-Q21/3 |
LoseAMRN / S&P -29.47% / 8.55% |
WinAMRN / S&P 13.63% / 6.58% |
LoseAMRN / S&P AMRN unavailable / 51.81% |
| 2021-Q12/3 |
WinAMRN / S&P 26.99% / 6.17% |
WinAMRN / S&P 17.55% / -1.06% |
LoseAMRN / S&P AMRN unavailable / 7.39% |
| 2020-Q42/3 |
WinAMRN / S&P 16.15% / 12.15% |
WinAMRN / S&P 42.89% / -3.72% |
LoseAMRN / S&P AMRN unavailable / -33.42% |
| 2020-Q31/3 |
LoseAMRN / S&P -39.16% / 8.93% |
WinAMRN / S&P 62.20% / -2.04% |
LoseAMRN / S&P AMRN unavailable / -27.10% |
| 2020-Q22/3 |
WinAMRN / S&P 73.00% / 20.54% |
WinAMRN / S&P 78.01% / -0.46% |
LoseAMRN / S&P AMRN unavailable / -27.11% |
| 2020-Q11/3 |
LoseAMRN / S&P -81.34% / -19.60% |
WinAMRN / S&P 97.80% / 3.47% |
LoseAMRN / S&P AMRN unavailable / -14.75% |
| 2019-Q42/3 |
WinAMRN / S&P 41.42% / 9.07% |
WinAMRN / S&P 87.49% / 5.36% |
LoseAMRN / S&P AMRN unavailable / 2.99% |
| 2019-Q31/3 |
LoseAMRN / S&P -21.82% / 1.70% |
WinAMRN / S&P 76.82% / 5.02% |
LoseAMRN / S&P AMRN unavailable / 0.21% |
| 2019-Q21/3 |
LoseAMRN / S&P -6.60% / 4.30% |
WinAMRN / S&P 55.08% / 6.64% |
LoseAMRN / S&P AMRN unavailable / 8.65% |
| 2019-Q12/3 |
WinAMRN / S&P 52.53% / 13.65% |
WinAMRN / S&P 35.82% / 8.12% |
LoseAMRN / S&P AMRN unavailable / 14.29% |
| 2018-Q41/3 |
LoseAMRN / S&P -16.35% / -13.52% |
WinAMRN / S&P 26.56% / 9.05% |
LoseAMRN / S&P AMRN unavailable / 18.23% |
| 2018-Q32/3 |
WinAMRN / S&P 426.54% / 7.71% |
WinAMRN / S&P 24.00% / 10.21% |
LoseAMRN / S&P AMRN unavailable / 19.06% |
| 2018-Q21/3 |
LoseAMRN / S&P 2.66% / 3.43% |
WinAMRN / S&P 30.72% / 9.03% |
LoseAMRN / S&P AMRN unavailable / 14.46% |
| 2018-Q11/3 |
LoseAMRN / S&P -24.94% / -0.76% |
WinAMRN / S&P 36.79% / 7.68% |
LoseAMRN / S&P AMRN unavailable / 12.46% |
| 2017-Q42/3 |
WinAMRN / S&P 14.57% / 6.64% |
WinAMRN / S&P 39.22% / 7.03% |
LoseAMRN / S&P AMRN unavailable / 13.82% |
| 2017-Q31/3 |
LoseAMRN / S&P -13.15% / 4.48% |
WinAMRN / S&P 40.60% / 5.68% |
LoseAMRN / S&P AMRN unavailable / 17.57% |
| 2017-Q22/3 |
WinAMRN / S&P 25.94% / 3.09% |
WinAMRN / S&P 41.71% / 4.83% |
LoseAMRN / S&P AMRN unavailable / 17.74% |
| 2017-Q11/3 |
LoseAMRN / S&P 3.90% / 6.07% |
WinAMRN / S&P 52.33% / 3.67% |
LoseAMRN / S&P AMRN unavailable / 13.32% |
| 2016-Q41/3 |
LoseAMRN / S&P -3.45% / 3.82% |
WinAMRN / S&P 59.11% / 2.09% |
LoseAMRN / S&P AMRN unavailable / 7.05% |
| 2016-Q32/3 |
WinAMRN / S&P 47.69% / 3.85% |
WinAMRN / S&P 64.83% / 0.20% |
LoseAMRN / S&P AMRN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | AMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -7.90% | 20.78% |
| Annualized return | -7.90% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | AMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -87.25% | 83.14% |
| Annualized return | -33.76% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | AMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -75.18% | 319.30% |
| Annualized return | -13.01% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |